Abstract A194: PEGylated human IL-10 (AM0010) in advanced solid tumors

ConclusionIn Monotherapy, AM0010 has a well-tolerated safety profile and leads to sustained and systemic immune stimulation. The pharmacodynamics and clinical activity observed support the ongoing monotherapy expansions and combination regimens with checkpoint inhibitors as well as cytotoxic chemotherapies.Trial registration: www.clinicaltrials.gov NCT02009449Citation Format: Jeffrey R. Infante, Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick A. Ott, Deborah J. Wong, Gerald S. Falchook, Manish Patel, Shubham Pant, Melinda Whiteside, Johanna C. Bendell, Todd M. Bauer, Filip Janku, Milind Javle, Rivka Colen, Nizar Tannir, Martin Oft. PEGylated human IL-10 (AM0010) in advanced solid tumors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A194.

Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Infante, J. R., Naing, A., Papadopoulos, K. P., Autio, K. A., Ott, P. A., Wong, D. J., Falchook, G. S., Patel, M., Pant, S., Whiteside, M., Bendell, J. C., Bauer, T. M., Janku, F., Javle, M., Colen, R., Tannir, N., Oft, M. Tags: Tumor Immunology Targets: Poster Presentations - Proffered Abstracts Source Type: research